Baird raises Taysha Gene Therapies stock price target to $12 on Rett syndrome study

Taysha Gene Therapies (TSHA) received multiple analyst price target boosts, including Baird raising its target to $12.00, following finalized FDA alignment for its pivotal 15-patient study of TSHA-102 in Rett syndrome. The FDA's Breakthrough Therapy designation, based on a 100% response rate in prior trials, along with Baird's assessment of the study as "highly likely to be successful," underscores the therapy's potential. With pivotal study enrollment slated for Q4 2025 and interim data in 2026, the company's significant regulatory and clinical progress has already fueled a 140% stock surge over the past six months.

Analysis

Taysha Gene Therapies (TSHA) has achieved significant regulatory de-risking for its lead asset, TSHA-102, a gene therapy for Rett syndrome. The company finalized alignment with the FDA on its pivotal trial protocol, securing a favorable 15-patient study size and a 6-month interim analysis timeline, which analysts at Baird noted appears 'highly likely to be successful.' This progress is further validated by the FDA's granting of Breakthrough Therapy designation, a decision supported by compelling clinical evidence from Phase 1/2 trials showing a 100% response rate in 12 patients. This string of positive developments has attracted strong bullish sentiment from the analyst community, with Baird raising its price target to $12.00, Cantor Fitzgerald maintaining a $13.00 target, and Canaccord Genuity increasing its target to $14.00. The market has responded enthusiastically, driving the stock up 140% over the past six months, pricing in a high probability of success ahead of the pivotal study's enrollment start in Q4 2025 and interim data expected in 2026.

Key Decisions for Investors

• Given the strong regulatory validation and unanimous analyst support, investors may view the recent 140% stock appreciation as a reflection of significant clinical de-risking, suggesting potential for further upside as key milestones are met.
• The primary focus should now be on execution and upcoming catalysts; monitor for the successful initiation of pivotal trial enrollment in Q4 2025, as the subsequent interim data readout in 2026 represents the next major value inflection point.
• Despite the positive momentum, investors should remain cognizant that significant future success is now priced into the stock, making it sensitive to any potential delays in the clinical timeline or unexpected trial outcomes.